Overview

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a 12 month non-interventional study with solifenacin succinate, evaluating the effect of solifenacin on quality of life (QoL) of patients previously treated with antimuscarinics (Males and Females with Overactive Bladder (OAB) symptoms withdrawing their treatment with antimuscarinics because of safety and/or efficacy reasons) - measured by Perception of Treatment Satisfaction (TS-VAS) and to evaluate the effect of solifenacin on quality of life measured by Over Active Bladder-q Short Form (OAB-q SF), EuroQol Group scoring system (EQ-5D-5L).
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Treatments:
Muscarinic Antagonists
Solifenacin Succinate